Neurocrine Biosciences
NBIX
#1205
Rank
C$22.49 B
Marketcap
$222.18
Share price
1.73%
Change (1 day)
16.62%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $2.63

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $2.84. In 2022 the company made an earnings per share (EPS) of $2.33 an increase over its 2021 EPS that were of $1.38.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$2.6312.87%
2022$2.3369.47%
2021$1.38-78.21%
2020$6.32990%
2019$0.5881.82%
2018$0.32-113.5%
2017-$2.360.62%
2016-$2.3557.28%
2015-$1.4925.61%
2014-$1.1918.84%
2013-$1.00-1085.71%
2012$0.10-89.71%
2011$0.99-500%
2010-$0.25-86.92%
2009-$1.88-43.48%
2008-$3.33-57.8%
2007-$7.9092.58%
2006-$4.10371.67%
2005-$0.87-52.76%
2004-$1.8436.56%
2003-$1.35-70%
2002-$4.49118.31%
2001-$2.068.4%
2000-$1.9048.86%
1999-$1.28-20%
1998-$1.59-479.31%
1997$0.42

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.03 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.80-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$4.29-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.87 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.33 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.70-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.68-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$4.39-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA